Royal Bank of Canada set a C$1.00 target price on Evogene (TSE:EVGN – Free Report) in a report issued on Wednesday,BayStreet.CA reports. The brokerage currently has a sector perform rating on the stock.
Separately, Desjardins dropped their target price on shares of Evogene from C$4.00 to C$3.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.
Check Out Our Latest Stock Analysis on EVGN
Evogene Stock Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Further Reading
- Five stocks we like better than Evogene
- Why is the Ex-Dividend Date Significant to Investors?
- Intuit’s AI Boom: Stock Soaring, But Should Investors Hit Pause?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Top Dividend Plays With Strong Analyst Ratings
- What Do S&P 500 Stocks Tell Investors About the Market?
- Robinhood Stock Keeps Giving Investors Reasons To Buy
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
